Promega Corporation has announced a distribution agreement with NimaGen to expand access to the latter's IDseek massively parallel sequencing library prep kits for forensic laboratories. The partnership enables labs to access NimaGen's RC-PCR technology through Promega's established global network. NimaGen's IDseek portfolio includes over 20 products supporting applications such as autosomal STR profiling, Y-chromosomal analysis, microhaplotype analysis and mitochondrial DNA sequencing. The technology enables single closed-tube reactions designed for degraded and low-quantity forensic samples. The agreement allows forensic laboratories already using Promega's sample preparation and capillary electrophoresis tools to transition to massively parallel sequencing workflows whilst maintaining their existing supplier relationships. Promega has supported forensic laboratories for over 30 years across human identification workflows.

Promega Corporation has launched the TarSeer BRETSA Target Engagement System, a live-cell platform for detecting ligand-protein interactions using bioluminescence resonance energy transfer. The technology measures compound binding to target proteins in cells through changes in thermal stability, even for proteins lacking known chemical probes. The platform has been applied to more than 20 target classes and supports 96- and 384-well formats. It aims to bridge the gap between biochemical and cellular assays for difficult-to-study proteins, helping researchers validate weak chemical compounds and expand accessible targets in drug discovery workflows. Promega will debut the technology at the SLAS International Conference in Boston on 7–11 February 2026. The system complements Promega's existing NanoBRET Target Engagement System by addressing targets unsuitable for NanoBRET analysis.

China's National Medical Products Administration has approved Promega's OncoMate Microsatellite Instability Detection Kit as a companion diagnostic for Merck's KEYTRUDA cancer therapy. This marks Promega's first companion diagnostic to receive NMPA approval. The PCR-based assay identifies MSI-High solid tumour patients who may benefit from pembrolizumab treatment. The approval addresses a critical need in China, which faces one of the world's highest cancer burdens, with most advanced solid tumour patients eventually progressing after first-line therapy. The approval resulted from collaboration with Merck and reflects shared commitment to improving diagnostic access. Promega's MSI technology has also received regulatory approvals in the EU and US. The kit will soon be available for purchase in China.